{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:43:05Z","timestamp":1787884985506,"version":"build-2784847793"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.cmi.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T03:45:44Z","timestamp":1431575144000},"page":"827-833","source":"Crossref","is-referenced-by-count":68,"title":["From the monovalent to the nine-valent HPV vaccine"],"prefix":"10.1016","volume":"21","author":[{"given":"S.","family":"Pils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Joura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2015.05.001_bib1","first-page":"1","article-title":"Human papillomaviruses and their possible role in squamous cell carcinomas","volume":"78","author":"zur Hausen","year":"1977","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cmi.2015.05.001_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.cmi.2015.05.001_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib4","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2015.05.001_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0042-6822(91)90533-H","article-title":"Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.cmi.2015.05.001_bib6","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A\u00a0controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cmi.2015.05.001_bib8","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.001_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2015.05.001_bib11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9576","key":"10.1016\/j.cmi.2015.05.001_bib13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib14","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: end-of-study analysis of a phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2015.05.001_bib15","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"issue":"9518","key":"10.1016\/j.cmi.2015.05.001_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"9686","key":"10.1016\/j.cmi.2015.05.001_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9706","key":"10.1016\/j.cmi.2015.05.001_bib20","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib21","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2015.05.001_bib22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib24","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2015.05.001_bib25","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2015.05.001_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0029-7844(97)00298-6","article-title":"Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia","volume":"90","author":"Jones","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cmi.2015.05.001_bib28","first-page":"613","article-title":"Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women","volume":"45","author":"Joura","year":"2000","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib29","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/01.AOG.0000210268.57527.a1","article-title":"Trends in the incidence of invasive and in situ vulvar carcinoma","volume":"107","author":"Judson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cmi.2015.05.001_bib30","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ejca.2009.07.019","article-title":"HPV infection in Europe","volume":"45","author":"De Vuyst","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2015.05.001_bib31","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","article-title":"Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva","volume":"49","author":"de Sanjose","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9574","key":"10.1016\/j.cmi.2015.05.001_bib32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A\u00a0pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.cmi.2015.05.001_bib34","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib35","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib36","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D\u2019Souza","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib37","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib39","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2015.05.001_bib40","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/infdis\/jit611","article-title":"A\u00a0case for immunization of human papillomavirus (HPV) 6\/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma","volume":"209","author":"Shah","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br J Cancer"},{"issue":"9961","key":"10.1016\/j.cmi.2015.05.001_bib42","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib44","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib45","doi-asserted-by":"crossref","first-page":"e93393","DOI":"10.1371\/journal.pone.0093393","article-title":"Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men","volume":"9","author":"Swedish","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2015.05.001_bib46","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2015.05.001_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12325-015-0178-4","article-title":"Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review","volume":"32","author":"Mariani","year":"2015","journal-title":"Adv Ther"},{"issue":"9783","key":"10.1016\/j.cmi.2015.05.001_bib48","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.001_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib50","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib51","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/cit436","article-title":"Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark","volume":"57","author":"Blomberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10552-014-0392-4","article-title":"Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program","volume":"25","author":"Baldur-Felskov","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.cmi.2015.05.001_bib54","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2015.01.084","article-title":"Reduction in HPV 16\/18\u2013associated high grade cervical lesions following HPV vaccine introduction in the United States\u20142008\u20132012","volume":"33","author":"Hariri","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.001_bib55","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ijc.28397","article-title":"A\u00a0pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer","volume":"134","author":"Mesher","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.cmi.2015.05.001_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","article-title":"Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England","volume":"32","author":"Mesher","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.001_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib58","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2015.05.001_bib59","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cmi.2015.05.001_bib60","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.cmi.2015.05.001_bib61","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cmi.2015.05.001_bib62","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2015.05.001_bib63","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2015.05.001_bib64","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/14760584.2014.935767","article-title":"Alternative dosage schedules with HPV virus\u2013like particle vaccines","volume":"13","author":"Stanley","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2015.05.001_bib65","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cmi.2015.05.001_bib66","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.27713","article-title":"Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe","volume":"132","author":"Tjalma","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2015.05.001_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.cmi.2015.05.001_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","article-title":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large US screening population: data from the ATHENA trial","volume":"137","author":"Monsonego","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","author":"Luxembourg","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2015.05.001_bib71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.001_bib72","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/INF.0000000000000694","article-title":"An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11\u201315 years of age","volume":"34","author":"Kosalaraksa","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2015.05.001_bib73","doi-asserted-by":"crossref","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2015.05.001_bib74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cmi.2015.05.001_bib75","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising expectations for subunit vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.001_bib76","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1415742","article-title":"HPV \u2018coverage\u2019","volume":"372","author":"Schuchat","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15004383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15004383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T16:50:14Z","timestamp":1537635014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15004383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1198743X15004383"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2015.05.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}